Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Prices $125M Public Stock Offering

NEW YORK — CareDx said on Wednesday that it has priced a planned $125 million public stock offering at $32 per share.

The Brisbane, California-based molecular diagnostics firm said it will offer 3,906,250 shares of its common stock through the transaction. It said it has also granted the underwriters of the offering a 30-day option to buy an additional 585,937 shares at the offering price, which would raise another $18.7 million.

The offering is expected to close on or around June 15. CareDx's stock closed at $33.51 on the Nasdaq Wednesday.

Goldman Sachs and Jefferies are acting as joint book-running managers for the offering. BTIG and Craig-Hallum Capital Group are acting as co-managers.

CareDx, which focuses on transplant medicine with products such as its AlloSure cell-free DNA test for organ transplant rejection, previously said it intends to use the proceeds from the offering for working capital and general corporate purposes.

In April, CareDx reported that it ended the first quarter with $32.2 million in cash and cash equivalents.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.